- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Nexalin-Studie belegt signifikante Schlafverbesserung bei Alzheimer-Patienten | 1 | Investing.com Deutsch | ||
| 27.10. | Nexalin study shows sleep improvement in Alzheimer's patients | 1 | Investing.com | ||
| 27.10. | Nexalin Technology, Inc.: Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS' Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease | 2 | GlobeNewswire (USA) | ||
| 08.10. | Nexalin Technology, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 08.10. | Nexalin Technology notifies Nasdaq compliance on minimum bid price | 2 | Seeking Alpha | ||
| 08.10. | Nexalin Technology, Inc.: Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing | 544 | GlobeNewswire (Europe) | HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the brain... ► Artikel lesen | |
| NEXALIN TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.10. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Why Is Nexalin Technology Stock Gaining Thursday? | 1 | Benzinga.com | ||
| 01.10. | Nexalin Technology, Inc.: Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation | 469 | GlobeNewswire (Europe) | Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync across seven countries and more than 300 million people, with a structured pricing framework... ► Artikel lesen | |
| 29.09. | Nexalin Technology, Inc.: Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy | 2 | GlobeNewswire (USA) | ||
| 29.09. | Nexalin appoints Robert DiTota as senior strategic advisor | 9 | Investing.com | ||
| 22.09. | Nexalin Technology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.09. | RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 878 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc. (NASDAQ:NXL) on the RedChip Small Stocks... ► Artikel lesen | |
| 03.09. | Nexalin Technology, Inc.: Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog ... | 3 | GlobeNewswire (USA) | ||
| 27.08. | Nexalin Technology beschließt Reverse-Aktiensplit im Verhältnis 1:30 | 3 | Investing.com Deutsch | ||
| 27.08. | Nexalin Technology approves 1-for-30 reverse stock split | 3 | Investing.com | ||
| 27.08. | Nexalin Technology announces 1-for-30 reverse stock split | 2 | Seeking Alpha | ||
| 27.08. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Nexalin Technology, Inc.: Nexalin Technology Announces Reverse Stock Split | 551 | GlobeNewswire (Europe) | HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), announces that its board of directors has approved a 1-for-30 reverse stock split... ► Artikel lesen | |
| 17.08. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,920 | -1,17 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,067 | 0,00 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 0,508 | -12,41 % | Cerenome names Ron Andrews as chief business officer | ||
| ATOSSA THERAPEUTICS | 1,950 | +1,04 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax | Total revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | -11,31 % | Tandem Diabetes Care names successor as CEO Sheridan retires | ||
| CO-DIAGNOSTICS | 0,289 | 0,00 % | Co-Diagnostics Reports Third Quarter 2026 Financial Results | Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and... ► Artikel lesen | |
| QUIDELORTHO | 10,730 | +3,82 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| VERU | 2,140 | +0,94 % | Veru executive to present obesity drug data at industry conference | ||
| LIFEWARD | 5,840 | +0,52 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,290 | -2,50 % | Clover Health auf der UBS Global Healthcare Conference: Starkes Wachstum trifft auf steigende Ertragskraft | ||
| SENSEONICS | 9,200 | +2,22 % | Senseonics delivers 'breakout quarter' more than doubling Eversense 365 revenue | ||
| TEMPEST THERAPEUTICS | 0,373 | 0,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 0,378 | +1,18 % | Nanox.AI signs distribution deal for cardiac imaging in Thailand | ||
| IMUNON | 0,780 | +13,04 % | IMUNON präsentiert translationale Daten aus Phase-2-Studie bei Eierstockkrebs |
NEXALIN TECHNOLOGY INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -2,04 % bei einem Aktienkurs von 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXALIN TECHNOLOGY INC finden Sie auf Wallstreet Online.